15,619 trials (keyword fallback)
Human Immunodeficiency Virus Infection · Sexually Transmitted Diseases
Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008
HIV
Primary: Condom Use/Unprotected Sex - Redefined as Sexual Risk - 12 Month Follow-up — 28; 18; 26; 40 Participants
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
Parkinson's Disease
Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Hypogonadism · Atherosclerosis
Primary: Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT) — 0.877; 0.879; 0.036; 0.033 mm
Pain · Hypogonadism
Primary: Brief Pain Inventory (BPI) at Week 14 — 10.2; 9.7; 5.3; 5.1 units on a scale
Reproductive Sterility
Primary: Number of Control and Treated Participants With Successful Live Births Following Conventional IVF or ICSI Cycles — 18; 13; 8; 9 participants
Human Immunodeficiency Virus (HIV) · Sexually Transmitted Disease (STD)
Primary: Consistent (100%) Condom Use — 9; 6; 7; 7 Participants — p=<.05
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1C — -0.20; -0.13 percent of hemoglobin A1c
Hypogonadism · Opioid-Related Disorders · Male Infertility
Primary: Serum Total Testosterone (Change From Baseline) — 322.5; 179.8 ng/mL
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
Urological
Primary: Mean and Standard Deviation of the Participant American Urological Association (AUA)Symptom Score Between Baseline and Week 72 for CAMUS Participants. — -2.20; -2.99…
Weight Loss
Primary: Mean Change in Weight by Randomized Group — -7.03; -4.14 kilograms
Prostatic Neoplasms
Primary: Change in Area Under the Plasma Concentration 0-8Hour (Hr)(AUC0-8hr) Values in Males Between Pre-Androgen Deprivation Therapy (ADT) and Post-ADT — 484.65; 473.05 Hr*ng/mL